Form 4 for ORMP ORAMED PHARMACEUTICALS INC.
Accepted 2026-03-18 00:00:00 ET · period of report 2026-03-17 · accession 0001213900-26-031011 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-18 | 2026-03-17 | ORMP | Gabay Avraham | CFO | A - Grant | $0.00 | +95.9K | 745.1K | +15% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-17 | A | A | 95,889 | $0.00 | 745,145 | D | — | — | (F1) Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer. |